BRPI0712206A2 - tratamento do agonista de melatonina - Google Patents

tratamento do agonista de melatonina Download PDF

Info

Publication number
BRPI0712206A2
BRPI0712206A2 BRPI0712206-3A BRPI0712206A BRPI0712206A2 BR PI0712206 A2 BRPI0712206 A2 BR PI0712206A2 BR PI0712206 A BRPI0712206 A BR PI0712206A BR PI0712206 A2 BRPI0712206 A2 BR PI0712206A2
Authority
BR
Brazil
Prior art keywords
agonist treatment
melatonin agonist
melatonin
treatment
agonist
Prior art date
Application number
BRPI0712206-3A
Other languages
English (en)
Inventor
Birznieks Gunther
Phadke Deepak
H. Polymeropoulos Mihael
Original Assignee
Vanda Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0712206(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals, Inc. filed Critical Vanda Pharmaceuticals, Inc.
Publication of BRPI0712206A2 publication Critical patent/BRPI0712206A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TRATAMENTO DO AGONISTA DE MELATONINA. A presente invenção refere-se a métodos de administração de (1R-trans)-N-[[2-(2,3-diidro-4-benzofuraniI)ciclopropiI]metil]propanam ida como um agonista do receptor de melatonina a um ser humano para tratar ou prevenir um distúrbio do ritmo circadiano ou distúrbio do sono.
BRPI0712206-3A 2006-05-22 2007-05-22 tratamento do agonista de melatonina BRPI0712206A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74784706P 2006-05-22 2006-05-22
US60/747847 2006-05-22
PCT/US2007/069411 WO2007137244A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment

Publications (1)

Publication Number Publication Date
BRPI0712206A2 true BRPI0712206A2 (pt) 2012-03-13

Family

ID=38723632

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712206-3A BRPI0712206A2 (pt) 2006-05-22 2007-05-22 tratamento do agonista de melatonina

Country Status (17)

Country Link
US (7) US20090105333A1 (pt)
EP (1) EP2028937B2 (pt)
JP (5) JP2009538332A (pt)
KR (2) KR101587394B1 (pt)
AU (3) AU2007253701A1 (pt)
BR (1) BRPI0712206A2 (pt)
CA (2) CA2666293C (pt)
CY (1) CY1120433T1 (pt)
DK (1) DK2028937T4 (pt)
ES (1) ES2532849T5 (pt)
MX (1) MX2008014841A (pt)
NL (1) NL300795I2 (pt)
PL (1) PL2028937T5 (pt)
PT (1) PT2028937E (pt)
RU (1) RU2488392C2 (pt)
WO (1) WO2007137244A1 (pt)
ZA (1) ZA200809529B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) † 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
JP5590676B2 (ja) * 2007-09-13 2014-09-17 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測
WO2011009102A1 (en) * 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
IL330095A (en) * 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
IL266159B2 (en) * 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
WO2019028245A1 (en) 2017-08-02 2019-02-07 Vanda Pharmaceuticals Inc. USE OF TASIMELTÉON FOR THE TREATMENT OF AFFECTIVE DISORDERS
EP3761974A1 (en) * 2018-03-04 2021-01-13 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
JP7432884B2 (ja) * 2018-03-26 2024-02-19 パナソニックＩｐマネジメント株式会社 サポートシステム、機器制御システム、サポートシステムの作動方法、及び、機器制御システムの作動方法
JP2022500420A (ja) * 2018-09-12 2022-01-04 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 睡眠又は睡眠後パフォーマンスの改善
SG11202108695QA (en) 2019-02-13 2021-09-29 Vanda Pharmaceuticals Inc Method of improving sleep
BR112021026463A2 (pt) * 2019-06-29 2022-02-08 Vanda Pharmaceuticals Inc Métodos para identificar um indivíduo a ser tratado por tempo de sono atrasado, para identificar um indivíduo em que o tempo de sono ou fase de sono pode ser atrasada, para identificar um indivíduo a ser tratado para um período circadiano alongado (tau), para identificar um indivíduo como alguém passível de alteração de um período circadiano (tau), e, para identificar um paciente a ser tratado para uma fase de sono atrasado devido ao tratamento com um inibidor de canal de nucleotídeo cíclico ativado por hiperpolarização (hcn)
NZ811397A (en) 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US5242941A (en) † 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
EP0813595A1 (en) * 1995-03-06 1997-12-29 Novo Nordisk A/S Stimulation of meiosis
KR100499106B1 (ko) * 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
EP1696959A2 (en) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
KR101187461B1 (ko) * 2005-07-29 2012-10-02 반다 파마슈티칼즈, 인코퍼레이티드. 각성을 향상시키는 방법
KR101587394B1 (ko) † 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
JP5590676B2 (ja) * 2007-09-13 2014-09-17 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測
IL330095A (en) * 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
US11918557B2 (en) * 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
IL266159B2 (en) * 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6921534B2 (ja) * 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
US20170326153A1 (en) † 2014-10-28 2017-11-16 Sandoz Ag Pharmaceutical Composition Consisting of Ceftaroline Fosamil Acetic Acid Solvate Particles Arginine Particles, Both Having A Specific Particle Size Distribution
US11013713B2 (en) * 2015-12-15 2021-05-25 Vanda Pharmaceuticals Inc. Method of treatment
SG11202108695QA (en) * 2019-02-13 2021-09-29 Vanda Pharmaceuticals Inc Method of improving sleep
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
EP2028937B1 (en) 2015-01-28
ES2532849T5 (es) 2018-10-18
NL300795I2 (pt) 2017-03-28
US20240325339A1 (en) 2024-10-03
US20200397741A1 (en) 2020-12-24
AU2021273588A1 (en) 2021-12-16
CA2950087A1 (en) 2007-11-29
AU2007253701A1 (en) 2007-11-29
JP2019089812A (ja) 2019-06-13
JP6659072B2 (ja) 2020-03-04
JP2017031183A (ja) 2017-02-09
AU2013207585B2 (en) 2016-04-28
EP2028937A1 (en) 2009-03-04
JP2015013875A (ja) 2015-01-22
JP2009538332A (ja) 2009-11-05
EP2028937B2 (en) 2018-06-27
PL2028937T3 (pl) 2015-10-30
KR101587394B1 (ko) 2016-01-21
US20150080464A1 (en) 2015-03-19
US20230021493A1 (en) 2023-01-26
EP2028937A4 (en) 2010-06-02
CA2666293A1 (en) 2007-11-29
ES2532849T3 (es) 2015-04-01
DK2028937T4 (en) 2018-09-03
JP6306114B2 (ja) 2018-04-04
US20180243258A1 (en) 2018-08-30
PL2028937T5 (pl) 2018-12-31
WO2007137244A1 (en) 2007-11-29
RU2008150622A (ru) 2010-06-27
JP6480050B2 (ja) 2019-03-06
MX2008014841A (es) 2008-12-05
ZA200809529B (en) 2009-12-30
KR20090034810A (ko) 2009-04-08
KR101571163B1 (ko) 2015-11-23
CA2666293C (en) 2017-01-10
US20160354337A1 (en) 2016-12-08
PT2028937E (pt) 2015-04-09
RU2488392C2 (ru) 2013-07-27
DK2028937T3 (en) 2015-04-07
AU2021273588B2 (en) 2023-03-02
CY1120433T1 (el) 2019-07-10
KR20150083932A (ko) 2015-07-20
JP2018109057A (ja) 2018-07-12
US20090105333A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
CY1120433T1 (el) Θεραπεια αγωνιστων μελατονινης
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
MX2009013989A (es) Terapia en combinacion para depresion.
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
ME01532B (me) Jedinjenja
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
EA201300869A1 (ru) Морфинановые соединения
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
BRPI0607529A2 (pt) compostos de azol neuroterapêuticos
BRPI0811842A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para aumentar a qualidade do sono em um paciente mamífero, para tratar a insônia em um paciente mamífero, e para tratar ou controlar a obesidade em um paciente mamífero
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
MX349754B (es) Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
GEAP201813377A (en) New therapeutical composition containing apomorphine as active ingredient
BR112014031360A2 (pt) derivado de metil amina cíclica heteroaromática
MX2010004878A (es) Derivados de tioeter y eter heterociclico y metodos de uso de los mismos.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MY150210A (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]